Accuracy and reliability of a commercial treatment planning system in nontarget regions in modern prostate radiotherapy.

Based on the currently available benchmarks our TPS is considered acceptable for clinical use, although the dose in some POIs was poorly predicted by the CC algorithm. Some areas were pointed out where TPSs and linear accelerator control systems can be improved.